CRBU

Caribou Biosciences, Inc.

Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. DE · CIK 0001619856
$1.64 -2.96% $162.7M
Insider Selling Cluster (4 insiders)5 New Institutional Positions5 Institutional Exits
Vol
Market Cap$162.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders50 funds
Inst. Value$38.0M
Inst. Activity5 buys / 5 sells
Insider Activity0B / 5S
Insider Net $-$47.5K
SEC Reports8
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001619856·Prev Close $1.69

Recent Activity

Jun 18, 2026 short_volume
Short Volume: CRBU — 70.0% short (0.7M / 1.1M)
Short: 742,068 | Exempt: 466 | TRF Vol: 1,059,931 | Short Ratio: 70.0% | Off-exchange volume (dark p
Jun 11, 2026 SEC
Caribou Biosciences announced long-term follow-up data from its ANTLER phase 1 (vispa-cel, anti-CD19) and CaMMouflage ph
8-K — Impact 6/10
Jun 5, 2026 SEC
Caribou Biosciences filed a DEFA14A urging stockholders to vote ahead of the June 17, 2026 annual meeting. The board rec
DEFA14A — Impact 2/10
Apr 24, 2026 SEC
Caribou Biosciences is holding its 2026 annual meeting where shareholders will vote on electing three Class II directors
DEFA14A — Impact 3/10
Feb 25, 2026 Insider
Kelly Timothy P sold 6,228 shares
Chief Technology Officer @ $1.93 ($12.0K)
Feb 24, 2026 Insider
MCCLUNG BARBARA G sold 6,938 shares
Chief Legal Officer @ $1.96 ($13.6K)
Feb 24, 2026 Insider
Albertson Tina M. sold 1,066 shares
Chief Medical Officer @ $1.96 ($2.1K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
2,590,497 shares ($4.9M)

Price Targets

$12.00 +631.7% upside Strong Buy
Current $1.64 Low $4.00 Median $10.00 High $32.00 7 analysts
$4.00 $32.00

Analyst Ratings

Strong Buy93% buy · 14 analysts
5Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 11, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy
Apr 7, 2026 HC Wainwright & Co. REITERATE Buy → Buy
Mar 9, 2026 Evercore ISI Group MAINTAIN Outperform → Outperform
Feb 2, 2026 Clear Street INITIATE Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.31 ▲ +2.6% $-0.33 — $-0.29 12% YoY 3
Next Q $-0.32 $-0.35 — $-0.29 3
Current FY $-1.25 ▲ +0.7% $-1.36 — $-1.15 3
Next FY $-1.40 ▲ +6.7% $-1.48 — $-1.32 -12% YoY 2

Latest Reports

BULLISH 8-K 6/10
Caribou Biosciences announced long-term follow-up data from its ANTLER phase 1 (vispa-cel, anti-CD19) and CaMMouflage ph
Jun 11, 2026
BULLISH Press 7/10
Caribou Biosciences reported longer follow-up data from the CaMMouflage Phase 1 trial of CB-011, an off-the-shelf BCMA-t
Jun 11, 2026
NEUTRAL DEFA14A 2/10
Caribou Biosciences filed a DEFA14A urging stockholders to vote ahead of the June 17, 2026 annual meeting. The board rec
Jun 5, 2026

Top Institutional Holders

FundValueMove
VANGUARD CAPITAL MANAGEMENT LLC$7.2M—
RENAISSANCE TECHNOLOGIES LLC$4.9MADD
BlackRock, Inc.$4.1MADD
TWO SIGMA INVESTMENTS, LP$3.3MADD
BANK OF AMERICA CORP$2.5MADD

Recent Insider Trades

DateInsiderTypeValue
Feb 25, 2026Kelly TimothySELL$12.0K
Feb 24, 2026MCCLUNG BARBARASELL$13.6K
Feb 24, 2026Albertson TinaSELL$2.1K
Feb 24, 2026Khan RuhiSELL$13.6K
Feb 24, 2026Kelly TimothySELL$6.2K
50 institutional holders with $38.0M total value (20,020,196 shares) as of 2026-Q1. Top holders: VANGUARD, RENAISSANCE, BlackRock,.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1VANGUARD CAPITAL MANAGEMENT LLC3,767,228$7.2M18.8%—
2RENAISSANCE TECHNOLOGIES LLC2,590,497$4.9M12.9%ADD +58.0%
3BlackRock, Inc.2,143,085$4.1M10.7%ADD +46.7%
4TWO SIGMA INVESTMENTS, LP1,759,934$3.3M8.8%ADD +30.2%
5BANK OF AMERICA CORP /DE/1,297,167$2.5M6.5%ADD +30.6%
6MARSHALL WACE, LLP1,205,668$2.3M6.0%ADD +36.8%
7MACKENZIE FINANCIAL CORP942,786$1.8M4.7%—
8SUSQUEHANNA INTERNATIONAL GROUP, LLP836,903$1.6M4.2%—
9FMR LLC723,959$1.4M3.6%—
10DIMENSIONAL FUND ADVISORS LP673,200$1.3M3.4%TRIM -33.1%
11CHARLES SCHWAB INVESTMENT MANAGEMENT INC559,642$1.1M2.8%TRIM -27.2%
12VANGUARD FIDUCIARY TRUST CO520,118$988.2K2.6%—
13STATE STREET CORP423,263$804.2K2.1%NEAR_EXIT -78.2%
14GOLDMAN SACHS GROUP INC376,589$715.5K1.9%—
15WELLS FARGO & COMPANY/MN303,655$576.9K1.5%DOUBLED +449.0%
16MORGAN STANLEY245,112$465.7K1.2%NEAR_EXIT -82.4%
17Point72 Asset Management, L.P.187,622$356.5K0.9%TRIM -53.6%
18SUSQUEHANNA INTERNATIONAL GROUP, LLP162,100$308.0K0.8%—
19CITADEL ADVISORS LLC159,033$302.2K0.8%—
20OMERS ADMINISTRATION Corp120,200$228.4K0.6%TRIM -32.5%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
RENAISSANCE TECHNOLOGIES LLCADD1,639,8572,590,497+58.0%$4.9M2026-Q1
BANK OF AMERICA CORP /DE/ADD993,1861,297,167+30.6%$2.5M2026-Q1
MARSHALL WACE, LLPADD881,1051,205,668+36.8%$2.3M2026-Q1
DIMENSIONAL FUND ADVISORS LPTRIM1,006,010673,200-33.1%$1.3M2026-Q1
Point72 Asset Management, L.P.TRIM403,938187,622-53.6%$356.5K2026-Q1
OMERS ADMINISTRATION CorpTRIM178,100120,200-32.5%$228.4K2026-Q1
Invesco Ltd.DOUBLED35,06383,502+138.1%$158.7K2026-Q1
CANADA PENSION PLAN INVESTMENT BOARDDOUBLED7,40057,900+682.4%$110.0K2026-Q1
AMERIPRISE FINANCIAL INCTRIM85,10429,430-65.4%$55.9K2026-Q1
CWM, LLCNEAR_EXIT575137-76.2%$260.002026-Q1
BlackRock, Inc.ADD1,459,3202,141,023+46.7%$3.4M2025-Q4
RENAISSANCE TECHNOLOGIES LLCDOUBLED780,4211,639,857+110.1%$2.6M2025-Q4
TWO SIGMA INVESTMENTS, LPADD783,5901,020,079+30.2%$1.6M2025-Q4
MARSHALL WACE, LLPDOUBLED125,844881,105+600.2%$1.4M2025-Q4
Point72 Asset Management, L.P.ADD288,547403,938+40.0%$642.3K2025-Q4
WELLS FARGO & COMPANY/MNDOUBLED25,854141,943+449.0%$225.7K2025-Q4
Invesco Ltd.DOUBLED12,20735,063+187.2%$55.8K2025-Q4
Russell Investments Group, Ltd.ADD13,52324,347+80.0%$38.7K2025-Q4
CWM, LLCNEAR_EXIT2,435575-76.4%$1.002025-Q4
BANK OF AMERICA CORP /DE/ADD808,9001,074,442+32.8%$2.5M2025-Q3
RENAISSANCE TECHNOLOGIES LLCADD532,121780,421+46.7%$1.8M2025-Q3
UBS Group AGADD249,103319,292+28.2%$744.0K2025-Q3
AMERIPRISE FINANCIAL INCTRIM308,95585,354-72.4%$198.9K2025-Q3
&PARTNERSNEAR_EXIT336,56544,139-86.9%$102.8K2025-Q3
ENVESTNET ASSET MANAGEMENT INCNEAR_EXIT318,65738,768-87.8%$90.3K2025-Q3
13 unique insiders with 24 transactions. Net insider value: -$47.5K ($0.00 bought, $47.5K sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Feb 25, 2026Kelly Timothy PChief Technology OfficerSELL6,228$1.93$12.0K
Feb 24, 2026MCCLUNG BARBARA GChief Legal OfficerSELL6,938$1.96$13.6K
Feb 24, 2026Albertson Tina M.Chief Medical OfficerSELL1,066$1.96$2.1K
Feb 24, 2026Khan Ruhi AhmadChief Business OfficerSELL6,938$1.96$13.6K
Feb 24, 2026Kelly Timothy PChief Technology OfficerSELL3,147$1.96$6.2K
Feb 20, 2026Zheng RanDirectorAWARD45,000——
Feb 20, 2026Whiting NancyDirectorAWARD45,000——
Feb 20, 2026Sacks NatalieDirectorAWARD45,000——
Feb 20, 2026Richardson-Heron DaraDirectorAWARD45,000——
Feb 20, 2026JOHNSON DAVID LEEDirectorAWARD45,000——
Feb 20, 2026GUGGENHIME ANDREWDirectorAWARD45,000——
Feb 20, 2026Braunstein ScottDirectorAWARD45,000——
Feb 20, 2026Ryali SriramChief Financial OfficerAWARD55,000——
Feb 20, 2026Ryali SriramChief Financial OfficerAWARD247,500——
Feb 20, 2026Haurwitz Rachel E.President and CEOAWARD151,700——
Feb 20, 2026Haurwitz Rachel E.President and CEOAWARD682,500——
Feb 20, 2026MCCLUNG BARBARA GChief Legal OfficerAWARD45,000——
Feb 20, 2026MCCLUNG BARBARA GChief Legal OfficerAWARD202,500——
Feb 20, 2026Albertson Tina M.Chief Medical OfficerAWARD55,000——
Feb 20, 2026Albertson Tina M.Chief Medical OfficerAWARD247,500——
Feb 20, 2026Khan Ruhi AhmadChief Business OfficerAWARD45,000——
Feb 20, 2026Khan Ruhi AhmadChief Business OfficerAWARD202,500——
Feb 20, 2026Kelly Timothy PChief Technology OfficerAWARD45,000——
Feb 20, 2026Kelly Timothy PChief Technology OfficerAWARD202,500——
8 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 6 neutral. Avg impact: 3.9/10.
BULLISH 8-K 6/10
Caribou Biosciences announced long-term follow-up data from its ANTLER phase 1 (vispa-cel, anti-CD19
Jun 11, 2026
NEUTRAL DEFA14A 2/10
Caribou Biosciences filed a DEFA14A urging stockholders to vote ahead of the June 17, 2026 annual me
Jun 5, 2026
NEUTRAL DEFA14A 3/10
Caribou Biosciences is holding its 2026 annual meeting where shareholders will vote on electing thre
Apr 24, 2026
MIXED 8-K 5/10
Caribou Biosciences reported its 2025 financial results, showing a slight improvement in net loss de
Mar 5, 2026
NEUTRAL INST-CLUSTER 5/10
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly i
Feb 28, 2026
NEUTRAL CLUSTER 3/10
Five C-suite executives at Caribou Biosciences sold shares in a coordinated 7-day window, generating
Feb 27, 2026
NEUTRAL CLUSTER, CLUSTER 4/10
Multiple C-suite executives at Caribou Biosciences (CRBU) sold shares in a coordinated cluster over
Feb 25, 2026
NEUTRAL CLUSTER 3/10
Two C-suite executives at Caribou Biosciences — the Chief Business Officer and Chief Medical Officer
Feb 25, 2026
BULLISH 7/10
Caribou Biosciences reported longer follow-up data from the CaMMouflage Phase 1 trial of CB-011, an
Jun 11, 2026
MIXED 6/10
Caribou Biosciences reported fourth quarter and full-year 2025 financial results, highlighting clini
Mar 5, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 5 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$12.00 mean target +631.7% upside Strong Buy (1.14)
$4.00 Low $32.00 High
MetricValue
Current Price$1.64
Target Low$4.00
Target Mean$12.00
Target Median$10.00
Target High$32.00
# Analysts7
RecommendationStrong Buy (1.14)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.31 $-0.33 $-0.29 12.4% +2.6% — $0.0B -15.8% 3
Next Q
2026-09-30
 $-0.32 $-0.35 $-0.29 — +0.0% — $0.0B -0.8% 3
Current FY
2026-12-31
 $-1.25 $-1.36 $-1.15 — +0.7% 0↑ 1↓ $0.0B 130.0% 3
Next FY
2027-12-31
 $-1.40 $-1.48 $-1.32 -12.3% +6.7% 0↑ 1↓ $0.0B 17.2% 2

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.307
7d ago$-0.315+0.008
30d ago$-0.315+0.008
60d ago$-0.340+0.033
90d ago$-0.340+0.033
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 11, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Apr 7, 2026 HC Wainwright & Co. REITERATE Buy Buy
Mar 9, 2026 Evercore ISI Group MAINTAIN Outperform Outperform
Feb 2, 2026 Clear Street INITIATE — Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20265810093%
May 1, 20265910093%
Apr 1, 20265910093%
Mar 1, 20265910093%
Feb 1, 20265810093%
Jan 1, 20265810093%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 18, 2026
short_volume
Short Volume: CRBU — 70.0% short (0.7M / 1.1M)
Short: 742,068 | Exempt: 466 | TRF Vol: 1,059,931 | Short Ratio: 70.0% | Off-exchange volume (dark pool + OTC)
Jun 17, 2026
short_volume
Short Volume: CRBU — 58.9% short (0.5M / 0.8M)
Short: 478,563 | Exempt: 4,500 | TRF Vol: 812,496 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
Jun 16, 2026
short_volume
Short Volume: CRBU — 74.3% short (0.6M / 0.8M)
Short: 562,447 | Exempt: 436 | TRF Vol: 756,996 | Short Ratio: 74.3% | Off-exchange volume (dark pool + OTC)
Jun 11, 2026
other
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
<p align="center"><em>-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS --</em></p
Jun 11, 2026
fda
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
<p align="center"><em>-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 9
Jun 10, 2026
short_volume
Short Volume: CRBU — 60.2% short (0.3M / 0.5M)
Short: 314,163 | Exempt: 0 | TRF Vol: 522,097 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: CRBU — 57.2% short (0.5M / 1.0M)
Short: 547,945 | Exempt: 0 | TRF Vol: 958,018 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: CRBU — 57.2% short (0.7M / 1.2M)
Short: 700,468 | Exempt: 29,234 | TRF Vol: 1,224,184 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: CRBU — 55.6% short (0.4M / 0.7M)
Short: 394,100 | Exempt: 5,677 | TRF Vol: 708,570 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: CRBU — 64.5% short (0.5M / 0.8M)
Short: 517,790 | Exempt: 1,600 | TRF Vol: 802,394 | Short Ratio: 64.5% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: CRBU — 57.5% short (0.5M / 1.0M)
Short: 546,864 | Exempt: 16,343 | TRF Vol: 951,095 | Short Ratio: 57.5% | Off-exchange volume (dark pool + OTC)
May 13, 2026
other
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
<p align="left">BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=zw4HaCv2dsVUzxLE3PCzYiiQJYH7W
May 12, 2026
routine
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
<p>BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=iqqAiy95rJoTlZugf-Y-SeIEzgGXOJwIJoAwiMd-LY
May 4, 2026
earnings_calendar
CRBU Q1 2026 Earnings Scheduled — 2026-05-04
Mar 5, 2026
earnings
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
<p>BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=OuLyMfRMYUPtCWHFn-RBquVcinkI-BXL4_pMZZUn